These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16785831)

  • 1. GI risk and risk factors of NSAIDs.
    Laine L
    J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S60-6. PubMed ID: 16785831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L
    Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal anti-inflammatory drugs versus selective COX-2 inhibitors in the upper gastrointestinal tract.
    Schölmerich J
    J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S67-71. PubMed ID: 16785832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
    Lanas A; Hunt R
    Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors.
    Lazzaroni M; Porro GB
    Drugs; 2009; 69(1):51-69. PubMed ID: 19192936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly.
    Lanas A; Ferrandez A
    Drugs Aging; 2007; 24(2):121-31. PubMed ID: 17313200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs.
    Peng S; Duggan A
    Expert Opin Drug Saf; 2005 Mar; 4(2):157-69. PubMed ID: 15794710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
    El-Serag HB; Graham DY; Richardson P; Inadomi JM
    Arch Intern Med; 2002 Oct; 162(18):2105-10. PubMed ID: 12374519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.
    Naesdal J; Brown K
    Drug Saf; 2006; 29(2):119-32. PubMed ID: 16454539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.